Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1853-1859

  Chen, Guo Qiang ^a   Zhou, Li ^b   Styblo, Miroslav ^c   Walton, Felecia ^c   Jing, Yongkui ^b   Weinberg, Rona ^b   Chen, Zhu ^a   Waxman, Samuel ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ARSINE DERIVATIVE; CACODYLIC ACID; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; IODODIMETHYLARSINE; METHANEARSONIC ACID; METHYLARSINE OXIDE; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; METHYLATION; PRIORITY JOURNAL; STEM CELL;

APOPTOSIS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; GLUTATHIONE PEROXIDASE; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROGEN PEROXIDE; K562 CELLS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIVER NEOPLASMS; LYMPHOMA; METHYLATION; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; TUMOR CELLS, CULTURED;

EID: 0037447171     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Pandolfi, P. P. PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia, Haematologica, 81: 472-82, 1996.
2. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. The PML-RAR α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66: 675-84, 1991.
3. Melnick, A., and Licht, J. D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia, Blood, 93: 3167-215, 1999.
4. Shen, Z. X., Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M., Qiu, Q. Y., Zhu, J., Tang, W., Sun, G, L., Yang, K. Q., Chen, Y., Zhou, L., Fang. Z. W., Wang, Y. T., Ma, J., Zhang, P., Zhang, T. D., Chen, S. J., Chen, Z., and Wang, Z. Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood, 89: 3354-60, 1997.
5. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, Jr., R. P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.
6. Cohen, M. H., Hirschfeld, S., Flamm Honig, S., Ibrahim, A., Johnson, J. R., O'Leary, J. J., White, R. M., Williams, G. A., and Pazdur, R. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist, 6: 4-11, 2001.
7. Degos, L. Differentiation therapy in acute promyelocytic leukemia: European experience. J. Cell Physiol., 173: 285-7, 1997.
8. Niu, C., Yan, H., Yu, T., Sun, H. P., Liu, J. X., Li, X. S., Wu, W., Zhang, F. Q., Chen, Y., Zhou, L., Li, J. M., Zeng, X. Y., Yang, R. R., Yuan, M. M., Ren, M. Y., Gu, F. Y., Cao, Q., Gu, B. W., Su, X. Y., Chen, G. Q., Xiong, S. M., Zhang, T. d., Waxman, S., Wang, Z. Y., Chen, Z., Hu, J., Shen, Z. X., and Chen, S. J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 94: 3315-24, 1999.
9. Aposhian, H. V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol., 37: 397-419, 1997.
10. Kitchin, K. T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol., 172: 249-61, 2001.
11. Del Razo, L. M., Styblo, M., Cullen, W. R., and Thomas, D. J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol., 174: 282-93, 2001.
12. Aposhian, H. V., Gurzau, E. S., Le, X. C., Gurzau, A., Healy, S. M., Lu, X., Ma, M., Yip, L., Zakharyan, R. A., Maiorino, R. M., Dart, R. C., Tircus, M. G., Gonzalez-Ramirez, D., Morgan, D. L., Avram, D., and Aposhian, M. M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol., 13: 693-7, 2000.
13. Styblo, M., Del Razo, L. M., Vega, L., Germolec, D. R., LeCluyse, E. L., Hamilton, G. A., Reed, W., Wang, C., Cullen, W. R., and Thomas, D. J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol., 74: 289-99, 2000.
14. Styblo, M., Drobna, Z., Jaspers, I., Lin, S., and Thomas, D. J. The role of biomethylation in toxicity and carcinogenicity of arsenic. A research update. Environ. Health Perspect., 110 SuppL 5: 767-771, 2002.
15. Petrick, J. S., Jagadish, B., Mash, E. A., and Aposhian, H. V. Monomethylarsonous acid (MMAIII) and arsenite: LD50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol., 14: 651-656, 2001.
16. Chen, G. Q., Shi, X. G., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z. G., Ni, J. H., Shi, G. Y., Jia, P. M., Liu, M. M., He, K. L., Niu, C., Ma, J., Zhang, P., Zhang, T. D., Paul, P., Naoe, T., Kitamura, K., Miller, W., Waxman, S., Wang, Z. Y., de The, H., Chen, S. J., and Chen, Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-53, 1997.
17. Lanotte, M., Martin-Thouvenin, V., Najman, S., Ballerini, P., Valensi, F., and Bergen, R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood, 77: 1080-1086, 1991.
18. Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J., Si, G. Y., Jin, X. L., Tang, W., Li, X. S., Xong, S. M., Shen, Z. X., Sun, G. L., Ma, J., Zhang, P., Zhang, T. D., Gazin, C., Naoe, T., Chen, S. J., Wang, Z. Y., and Chen, Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 88: 1052-61, 1996.
19. Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., Avvisati, G., Testa, U., Peschle, C., Gambacorti-Passerini, C., Nervi, C., and Miller, W. H., Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst., 90, 124-33, 1998.
20. Jing, Y., Dai, J., Cahlmers-Redman, R. M. E., Tatton, W., and Waxman, S. arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide dependent pathway. Blood, 94: 2102-11, 1999.
21. Cullen, W. R., McBride, B. C., and Reglinski, J. The reaction of methylarsenicals with thiols: some biological implications. J. Inorganic Biochem., 21: 179-194, 1984.
22. Styblo, M., Serves, S. V., Cullen, W. R., and Thomas, D. J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol., 10: 27-33, 1997.
23. Reay, P. F., and Asher, C. J. Preparation and purification of 74As-labeled arsenate and arsenite for use in biological experiments. Anal. Biochem., 78: 557-60, 1977.
24. Styblo, M., Yamauchi, H., and Thomas, D. J. Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol. Appl. Pharmacol., 135: 172-8, 1995.
25. Rosenauer, A., Raelson, J. V., Nervi, C., Eydoux, P., DeBlasio, A., and Miller, W. H., Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood. 88: 2671-82, 1996.
26. Borden, K. L., Boddy, M. N., Lally, J., O'Reilly, N. J., Martin, S., Howe, K., Solomon, E., and Freemont, P. S. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J., 14: 1532-41, 1995.
27. Styblo, M., Del Razo, L. M., LeCluyse, E. L., Hamilton, G. A., Wang, C., Cullen, W. R., and Thomas, D. J. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem. Res. Toxicol., 12: 560-5, 1999.
28. Styblo, M., Hughes, M. F., and Thomas, D. J. Liberation and analysis of protein-bound arsenicals. J Chromatogr B Biomed Appl., 677: 161-6, 1996.
29. Jing, Y., Wang, L., Xia, L., Chen, G. Q., Chen, Z., Miller, W. H., and Waxman, S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 97: 264-9, 2001.
30. Zhu, X. H., Shen, Y. L., Jing, Y. K., Cai, X., Jia, P. M., Huang, Y., Tang, W., Shi, G. Y., Sun, Y. P., Dai, J., Wang, Z. Y., Chen, s. J., Zhang, T. D., Waxman, S., Chen, Z., and Chen, G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst., 91: 772-778, 1999.
31. Dai, J., Weinberg, R. S., Waxman, S., and Jing, Y. Malignant cells can be sensitixed to undergo growth inhibition and apoptosis by arsenic trioxide trough modulation of the glutathione redox system. Blood, 93: 268-277, 1999.
32. Thomas, D. J., Styblo, M., and Lin, S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol., 176: 127-44, 2001.
33. Mass, M. J., Tennant, A., Roop, B. C., Cullen, W. R., Styblo, M., Thomas, D. J., and Kligerman, A. D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol., 14: 355-61, 2001.
34. Drobna, Z., Jaspers, I., Thomas, D. J., and Styblo, M. Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J., 17: 67-69, 2003.
35. Tappel, A. L. selenium-glutathione peroxidase: properties and synthesis. Curr. Topics Cell. Regul., 24: 87-97, 1984.
36. Bram, S., Froussard, P., Guichard, M., Jasmin, C., Augery, Y., Sinoussi-Barre, F., and Wray, W. Vitamin C preferential toxicity for malignant melanoma cells. Nature (Lond.), 284: 629-31, 1980.